Impact of stress on cancer metastasis

Future Oncology

Volumn 6, Issue 12, 2010, Pages 1863-1881

  Moreno Smith, Myrthala ^a   Lutgendorf, Susan K ^b,c,d   Sood, Anil K ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b UNIVERSITY OF IOWA   (United States)

^c UNIVERSITY OF IOWA   (United States)

^d UNIVERSITY OF IOWA HOSPITALS AND CLINICS   (United States)

Author keywords

cancer; catecholamine; metastasis; signaling pathway; stress

Indexed keywords

ADRENERGIC RECEPTOR; BETA ADRENERGIC RECEPTOR; CATECHOLAMINE; DOPAMINE; GLUCOCORTICOID; GLUCOCORTICOID RECEPTOR; HYDROCORTISONE; PROLACTIN; SUBSTANCE P;

CANCER GROWTH; CELL ADHESION; CELL INVASION; CELL MIGRATION; CELL PROLIFERATION; CELL SURVIVAL; CENTRAL NERVOUS SYSTEM; FORCED SWIMMING TEST; HUMAN; HYPOTHERMIA; IMMUNE RESPONSE; METASTASIS; NEUROENDOCRINE SYSTEM; NONHUMAN; OVARY; PERITONEUM; PRIORITY JOURNAL; PSYCHOSOCIAL ENVIRONMENT; REVIEW; SIGNAL TRANSDUCTION; STRESS; SURGICAL STRESS;

ANIMALS; DISEASE PROGRESSION; HOLISTIC HEALTH; HUMANS; IMMUNE SYSTEM; NEOPLASM METASTASIS; NEOPLASMS; NEUROSECRETORY SYSTEMS; SOCIAL ISOLATION; STRESS, PHYSIOLOGICAL; STRESS, PSYCHOLOGICAL;

EID: 78650429839     PISSN: 14796694     EISSN: 17448301     Source Type: Journal    
DOI: 10.2217/fon.10.142     Document Type: Review

References (261)

1. Fidler IJ: The role of organ microenvironment in the biology and therapy of cancer metastasis. J. Cell. Biochem. 101, 927-936 (2007).
2. Fidler IJ: The organ microenvironment and cancer metastasis. Differentiation 70(9-10), 498-505 (2002).
3. Spiegel D, Giese-Davis J: Depression and cancer: mechanisms and disease progression. Biol. Psychiatry 54(3), 269-282 (2003).
4. Bukberg J, Penman D, Holland JC: Depression in hospitalized cancer patients. Psychosom. Med. 46, 199-212 (1984).
5. Spiegel D: Health caring: psychosocial support for patients with cancer. Cancer 74(4), 1453-1457 (1994).
6. Chida Y, Hamer M, Wardle J et al.: Do stress-related psychosocial factors contribute to cancer incidence and survival? Nat. Clin. Pract. Oncol. 5(8), 466-475 (2008).
7. Duijts SF, Zeegers MP, Borne BV: The association between stressful life events and breast cancer risk: a meta-analysis. Int. J. Cancer 107(6), 1023-1029 (2003).
8. Lillberg K, Verkasalo P, Kaprio J et al.: Stressful life events and risk of breast cancer in 10,808 women: a cohort study. Am. J. Epidemiol. 157(5), 415-423 (2003).
9. Geyer S: Life events prior to manifestation of breast cancer: a limited prospective study covering eight years before diagnosis. J. Psychosom. Res. 35(2-3), 355-363 (1991).
10. Michael YL, Carlson NE, Chlebowski RT et al.: Influence of stressors on breast cancer incidence in the Womens Health Initiative. Health Physiol. 28, 137-146 (2009).
11. Steel JL GD, Gamblin TC, Olek MC, Carr BI: Depression, immunity, and survival in patients with hepatobiliary carcinoma. J. Clin. Oncol. 25, 2397-2405 (2007).
12. Satin JR, Linden W, Phillips MJ: Depression as a predictor of disease progression and mortality in cancer patients: a meta-analysis. Cancer 22, 5349-5361 (2009).
13. Everson SA, Goldberg DE, Kaplan GA et al.: Hopelessness and risk of mortality and incidence of myocardial infarction and cancer. Psychosom. Med. 58(2), 113-121 (1996).
14. Stommel M, Given BA, Given CW: Depression and functional status as predictors of death among cancer patients. Cancer 94(10), 2719-2727 (2002).
15. Watson M, Haviland JS, Greer S et al.: Influence of psychological response on survival in breast cancer: a population-based cohort study. Lancet 354(9187), 1331-1336 (1999).
16. Buccheri G: Depressive reactions to lung cancer are common and often followed by a poor outcome. Eur. Respir. J. 11(1), 173-178 (1998).
17. Cohen S, Willis TA: Stress, social support, and the buffering hypothesis. Psychol. Bull. 98, 310-357 (1985).
18. Funch DP, Marshall J: The role of stress, social support and age in survival from breast cancer. J. Psychosom. Res. 27, 77-83 (1983). (Pubitemid 13163605)
19. Marshall JR, Funch DP: Social environment and breast cancer. A cohort analysis of patient survival. Cancer 52(8), 1546-1550 (1983).
20. Maunsell E, Brisson J, Deschenes L: Social support and survival among women with breast cancer. Cancer 76(4), 631-637 (1995).
21. Giraldi T, Rodani MG, Cartei G et al.: Psychosocial factors and breast cancer: a 6-year Italian follow-up study. Psychother. Psychosom. 66(5), 229-236 (1997).
22. Butow PN, Hiller JE, Price MA et al.: Epidemiological evidence for a relationship between life events, coping style, and personality factors in the development of breast cancer. J. Psychosom. Res. 49(3), 169-181 (2000).
23. Kroenke CH, Kubzansky LD, Schernhammer ES et al.: Social networks, social support, and survival after breast cancer diagnosis. J. Clin. Oncol. 24(7), 1105-1111 (2006).
24. Sapolsky RM: Why Zebras Dont Get Ulcers: A Guide to Stress, Stress-Related Diseases, and Coping. WH Freeman and Co., NY, USA (1998).
25. Chrousos G: Stress and disorders of the stress system. Nat. Rev. Endocrinol. 5, 374-381 (2009).
26. McEwen B: Stress and health: relevance to persian gulf veterans? Presented at: International Society for Traumatic Stress Studies Annual Meeting 1998. Washington, DC, USA, 21-23 November 1998.
27. Schmidt C, Kraft K: b-endorphin and catecholamine concentrations during chronic and acute stress in intensive care patients. Eur. J. Med. Res. 1(11), 528-532 (1996).
28. Rupp Kiecolt-Glaser J.K.B.C.H, Dhalla KS, Dhalla NS: Mechanisms of cardiac cell damage due to catecholamines: significance of drugs regulating central sympathetic outflow. J. Cardiovasc. Pharmacol. 24(Suppl. 1), S16-S24 (1994).
29. Rupp H, Jacob R: Excess catecholamines and the metabolic syndrome: should central imidazoline receptors be a therapeutic target? Med. Hypotheses 44(3), 217-225 (1995).
30. Puglisi-Allegra S, Imperato A, Angelucci L et al.: Acute stress induces time-dependent responses in dopamine mesolimbic system. Brain Res. 554(1-2), 217-222 (1991).
31. Imperato A, Angelucci L, Casolini P et al.: Repeated stressful experiences differently affect limbic dopamine release during and following stress. Brain Res. 577(2), 194-199 (1992).
32. Seeman TE, Berkman LF, Blazer D et al.: Social ties and support and neuroendocrine function: the McArthur studies of successful aging. Ann. Behav. Med. 16(95-106), (1994).
33. Seeman TE, McEwen BS: Impact of social environment characteristics on neuroendocrine regulation. Psychosom. Med. 58(5), 459-471 (1996).
34. Seeman TE SB, Rowe JW, Horwitz RI, McEwen B: Price of adaptation-allostatic load and its health consequences. Arch. Intern. Med. 157, 2259-2268 (1997).
35. Kiecolt-Glaser JK BC, Glaser R, Malarkey WB: Love, marriage, and divorce: newlyweds stress hormones foreshadow relationship changes. J. Consult. Clin. Psychol. 71, 176-188 (2003).
36. Tyrka AR, Wier L, Price LH et al.: Childhood parental loss and adult hypothalamic- pituitary-adrenal function. Biol. Psychiatry 63, 1147-1154 (2008).
37. Bevans K, Cerbone A, Overstreet S: Relations between recurrent trauma exposure and recent life stress and salivary cortisol among children. Develop. Psychopathol. 20, 257-272 (2008).
38. Hughes J, Watkins L, Blumenthal JA et al.: Depression and anxiety symptoms are related to increased 24-hour urinary norepinephrine excretion among healthy middle-aged women. J. Psychosom. Res. 57, 353-358 (2004).
39. Grossman F, Potter WZ: Catecholamines in depression: a cumulative study of urinary norepinephrine and its major metabolites in unipolar and bipolar depressed patients versus healthy volunteers at the NIMH. Psychiatry Res. 87, 21-27 (1999).
40. Lake C, Pickar D, Ziegler MG et al.: High plasma norepinephrine levels in patients with major affective disorder. Am. J. Psychiatry 139, 1315-1318 (1982).
41. McEwen B: Physiology and neurobiology of stress and adaptation: central role of the brain. Physiol. Rev. 87, 873-904 (2007).
42. Ebner K RN, Saria A, Singewald N: Substance P in the medial amygdala: emotional stress-sensitive release and modulation of anxiety-related behavior in rats. Proc. Natl Acad. Sci. USA 101, 4280-4285 (2004).
43. Lakshmanan J: Nerve growth factor levels in mouse serum: variations due to stress. Neurochem. Res. 12, 393-397 (1987).
44. Lara HE, Porcile A, Espinoza J et al.: Release of norepinephrine from human ovary: coupling to steroidogenic response. Endocrine 15(2), 187-192 (2001).
45. Greenwald G, Roy S: Follicular development and its control. In: The Physiology of Reproduction. Knobil E, Neill J (Eds). Raven Press, NY, USA, 629-724 (1994).
46. Nankova B, Kvetnansky R, Hiremagalur B et al.: Immobilization stress elevates gene expression for catecholamine biosynthetic enzymes and some neuropeptides in rat sympathetic ganglia: effects of adrenocorticotropin and glucocorticoids. Endocrinology 137(12), 5597-5604 (1996).
47. Paredes A, Galvez A, Leyton V et al.: Stress promotes development of ovarian cysts in rats: the possible role of sympathetic nerve activation. Endocrine 8(3), 309-315 (1998).
48. Lara HE, Dorfman M, Venegas M et al.: Changes in sympathetic nerve activity of the mammalian ovary during a normal estrous cycle and in polycystic ovary syndrome: studies on norepinephrine release. Microsc. Res. Tech. 59(6), 495-502 (2002).
49. Maestroni GJ: Neurohormones and catecholamines as functional components of the bone marrow microenvironment. Ann. NY Acad. Sci. 917, 29-37 (2000).
50. Kobilka B: Adrenergic receptors as models for G protein-coupled receptor. Annu. Rev. Neurosci. 15, 87-114 (1992).
51. Pullar CE, Isseroff RR: The b-2-adrenergic receptor activates pro-migratory and pro-proliferative pathways in dermal fibroblasts via divergent mechanisms. J. Cell Sci. 119(Pt 3), 592-602 (2006).
52. Lai LP Mitchell J: b2-adrenergic receptors expressed on murine chondrocytes stimulate cellular growth and inhibit the expression of Indian hedgehog and collagen type X. J. Cell Biochem. 104, 545-553 (2008).
53. Bylund D, Blaxall HS, Iversen LJ, Caron MG, Lefkowitz RJ, Lomasney JW: Pharmacological characteristics of a 2-adrenergic receptors: comparison of pharmacologically defined subtypes with subtypes identified by molecular cloning. Mol. Pharmacol. 42, 1-5 (1992).
54. Fernando M, Heaney AP: a1-adrenergic receptor antagonists: novel therapy for pituitary adenomas. Mol. Endocrinol. 19(12), 3085-3096 (2005).
55. Badino GR, Novelli A, Girardi C et al.: Evidence for functional b-adrenoceptor subtypes in CG-5 breast cancer cell. Pharmacol. Res. 33(4-5), 255-260 (1996).
56. Lutgendorf SK, Cole S, Costanzo E et al.: Stress-related mediators stimulate vascular endothelial growth factor secretion by two ovarian cancer cell lines. Clin. Cancer Res. 9(12), 4514-4521 (2003).
57. McDonald PH, Lefkowitz RJ: b-arrestins: new roles in regulating heptahelical receptors functions. Cell Signal 13(10), 683-689 (2001).
58. Dixon RA, Kobilka BK, Strader DJ et al.: Cloning of the gene and cDNA for mammalian b-adrenergic receptor and homology with rhodopsin. Nature 321(6065), 75-79 (1986).
59. Emorine LJ, Marullo S, Briend-Sutren MM et al.: Molecular characterization of the human b-3-adrenergic receptor. Science 245(4922), 1118-1121 (1989).
60. Frielle T, Collins S, Daniel KW et al.: Cloning of the cDNA for the human b 1-adrenergic receptor. Proc. Natl Acad. Sci. USA 84(22), 7920-7924 (1987).
61. Thaker PH, Han LY, Kamat AA et al.: Chronic stress promotes tumor growth and angiogenesis in a mouse model of ovarian carcinoma. Nat. Med. 12(8), 939-944 (2006).
62. Rhen T Cidlowski J: Anti-inflammatory action of glucocorticoids - new mechanisms for old drugs. N. Engl. J. Med. 353(16), 1711 (2005).
63. Newton R: Molecular mechanisms of glucocorticoid action: what is important? Thorax 55(7), 603-613 (2000).
64. Pazirandeh A , Xue Y, Prestegaard T et al.: Effects of altered glucocorticoid sensitivity in the T cell lineage on thymocyte and T cell homeostasis. FASEB J. 16(7), 727-729 (2002).
65. Chrousos GP, Gold PW: The concepts of stress and stress system disorders. Overview of physical and behavioral homeostasis. JAMA 267(9), 1244-1252 (1992).
66. Sapolsky RM, Romero LM, Munck AU: How do glucocorticoids influence stress responses? Integrating permissive, suppressive, stimulatory, and preparative actions. Endocr. Rev. 21(1), 55-89 (2000).
67. Antoni MH, Cruess S, Cruess DG et al.: Cognitive-behavioral stress management reduces distress and 24-hour urinary free cortisol output among symptomatic HIV-infected gay men. Ann. Behav. Med. 22(1), 29-37 (2000).
68. Sephton S, Spiegel D: Circadian disruption in cancer: a neuroendocrine-immune pathway from stress to disease? Brain Behav. Immun. 17(5), 321-328 (2003).
69. Sephton SE, Sapolsky RM, Kraemer HC et al.: Diurnal cortisol rhythm as a predictor of breast cancer survival. J. Natl Cancer Inst. 92(12), 994-1000 (2000).
70. Schernhammer ES, Laden F, Speizer FE et al.: Night-shift work and risk of colorectal cancer in the nurses health study. J. Natl Cancer Inst. 95(11), 825-828 (2003).
71. Kawamura A, Tamaki N, Kokunai T: Effect of dexamethasone on cell proliferation of neuroepithelial tumor cell lines. Neurol. Med. Chir. (Tokyo) 38(10), 633-638; discussion 638-640 (1998).
72. Nakane T, Szentendrei T, Stern L et al.: Effects of IL-1 and cortisol on b-adrenergic receptors, cell proliferation, and differentiation in cultured human A549 lung tumor cells. J. Immunol. 145(1), 260-266 (1990).
73. Sheridan JF, Feng NG, Bonneau RH et al.: Restraint stress differentially affects anti-viral cellular and humoral immune responses in mice. J. Neuroimmunol. 31(3), 245-255 (1991).
74. Padgett DA, Marucha PT, Sheridan JF: Restraint stress slows cutaneous wound healing in mice. Brain Behav. Immun. 12(1), 64-73 (1998).
75. Padgett DA, Sheridan JF, Dorne J et al.: Social stress and the reactivation of latent herpes simplex virus type 1. Proc. Natl Acad. Sci. USA 95(12), 7231-7235 (1998).
76. Iwakabe K, Shimada M, Ohta A et al.: The restraint stress drives a shift in Th1/Th2 balance toward Th2-dominant immunity in mice. Immunol. Lett. 62(1), 39-43 (1998).
77. Fiserova A, Starec M, Kuldova M et al.: Effects of D2-dopamine and a-adrenoceptor antagonists in stress induced changes on immune responsiveness of mice. J. Neuroimmunol. 130(1-2), 55-65 (2002).
78. Nukina H, Sudo N, Aiba Y et al.: Restraint stress elevates the plasma interleukin-6 levels in germ-free mice. J. Neuroimmunol. 115(1-2), 46-52 (2001).
79. Zhou D, Kusnecov AW, Shurin MR et al.: Exposure to physical and psychological stressors elevates plasma interleukin 6: relationship to the activation of hypothalamic-pituitary-adrenal axis. Endocrinology 133(6), 2523-2530 (1993).
80. Zorzet S, Perissin L, Rapozzi V et al.: Restraint stress reduces the antitumor efficacy of cyclophosphamide in tumor-bearing mice. Brain Behav. Immun. 12(1), 23-33 (1998).
81. Steplewski Z, Vogel WH, Ehya H et al.: Effects of restraint stress on inoculated tumor growth and immune response in rats. Cancer Res. 45(10), 5128-5133 (1985).
82. Cao L, Filipov NM, Lawrence DA: Sympathetic nervous system plays a major role in acute cold/restraint stress inhibition of host resistance to Listeria monocytogenes. J. Neuroimmunol. 125(1-2), 94-102 (2002).
83. Steplewski Z, Goldman PR, Vogel WH: Effect of housing stress on the formation and development of tumors in rats. Cancer Lett. 34(3), 257-261 (1987).
84. Tjurmina OA, Armando I, Saavedra JM et al.: Exaggerated adrenomedullary response to immobilization in mice with targeted disruption of the serotonin transporter gene. Endocrinology 143(12), 4520-4526 (2002).
85. Kvetnansky R, Fukuhara K, Pacak K et al.: Endogenous glucocorticoids restrain catecholamine synthesis and release at rest and during immobilization stress in rats. Endocrinology 133(3), 1411-1419 (1993).
86. Ghoshal K, Wang Y, Sheridan JF, Jacob ST: Metallothionein induction in response to restraint stress. Transcriptional control, adaptation to stress, and role of glucocorticoid. J. Biol. Chem. 273, 27904-27910 (1998).
87. Ben-Eliyahu S, Yirmiya R, Liebeskind JC, Taylor AN, Gale RP: Stress increases metastatic spread of a mammary tumor in rats: evidence for mediation by the immune system. Brain Behav. Immun. 5(2), 193-205 (1991).
88. Ben-Eliyahu S, Page GG, Yirmiya R et al.: Evidence that stress and surgical interventions promote tumor development by suppressing natural killer cell activity. Int. J. Cancer. 80(6), 880-888 (1999).
89. Page GG, Ben-Eliyahu S: A role for NK-cells in greater susceptibility of young rats to metastatic formation. Develop. Comp. Immunol. 23(1), 87-96 (1999).
90. Page GG, Ben-Eliyahu S, Yirmiya R et al.: Morphine attenuates surgery-induced enhancement of metastatic colonization in rats. Pain 54(1), 21-28 (1993).
91. Ben-Eliyahu S, Shakhar G, Rosenne E et al.: Hypothermia in barbiturate-anesthetized rats suppresses natural killer cell activity and compromises resistance to tumor metastasis: a role for adrenergic mechanisms. Anesthesiology 91(3), 732-740 (1999).
92. Hermes GL, Delgado B, Tretiakova M et al.: Social isolation dysregulates endocrine and behavioral stress while increasing malignant burden of spontaneous mammary tumors. Proc. Natl Acad. Sci. USA 106(52), 22393-22398 (2009).
93. Hermes GL, Rosenthal L, Montag A, McClintock MK: Social isolation and the inflammatory response: sex differences in the enduring effects of a prior stressor. Am. J. Physiol. Regul. Integr. Comp. Physiol. 290(2), R273-R282 (2006).
94. Sharp J, Zammit T, Azar T, Lawson D: Stress-like responses to common procedures in individually and group-housed female rats. Contemp. Top. Lab. Anim. Sci. 42, 9-18 (2003).
95. Fisher ER, Fisher B: Recent observations on concepts of metastasis. Arch. Pathol. 83(4), 321-324 (1967).
96. Folkman J: How is blood vessel growth regulated in normal and neoplastic tissue? - G.H.A. Clowes Memorial Award Lecture. Cancer Res. 46(2), 467-473 (1986).
97. Liotta LA: Tumor invasion and metastases-role of the extracellular matrix: Rhoads Memorial Award Lecture. Cancer Res. 46(1), 1-7 (1986).
98. Fidler IJ: The pathogenesis of cancer metastasis: the seed and soil hypothesis revisited. Nat. Rev. Cancer 3(6), 453-458 (2003).
99. Folkman J: Toward an understanding of angiogenesis: search and discovery. Perspect. Biol. Med. 29(1), 10-36 (1985).
100. Langley RR, Fidler IJ: Tumor cell-organ microenvironment interactions in the pathogenesis of cancer metastasis. Endocr. Rev. 28(3), 297-321 (2007).
101. Senger DR, Galli SJ, Dvorak AM et al.: Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid. Science 219(4587), 983-985 (1983).
102. Spannuth WA, Sood AK, Coleman RL: Angiogenesis as a strategic target for ovarian cancer therapy. Nat. Clin. Pract. Oncol. 5(4), 194-204 (2008).
103. Ferrara N: Vascular endothelial growth factor. Eur. J. Cancer 32A(14), 2413-2422 (1996).
104. Ferrara N, Davis-Smyth T: The biology of vascular endothelial growth factor. Endocr. Rev. 18(1), 4-25 (1997).
105. Fredriksson JM, Lindquist JM, Bronnikov GE et al.: Norepinephrine induces vascular endothelial growth factor gene expression in brown adipocytes through a b-adrenoreceptor/ cAMP/protein kinase-A pathway involving Src but independently of ERK1/2. J. Biol. Chem. 275(18), 13802-13811 (2000).
106. Yang E, Donovan EL, Benson DM, Glaser R: VEGF is differentially regulated in multiple myeloma-derived cell lines by norepinephrine. Brain Behav. Immun. 22, 318-322 (2008).
107. Lutgendorf SK, Johnsen EL, Cooper B et al.: Vascular endothelial growth factor and social support in patients with ovarian carcinoma. Cancer 95(4), 808-815 (2002). (Pubitemid 34839673)
108. Lutgendorf SK, Lamkin DM, Jennings NB et al.: Biobehavioral influences on matrix metalloproteinase expression in ovarian carcinoma. Clin. Cancer Res. 14, 6839-6846. (2008).
109. Sharma A, Greenman J, Sharp DM, Walker LG, Monson JR: Vascular endothelial factor and psychosocial factors in colorectal cancer. Psychooncology 17(1), 66-73 (2008).
110. Costanzo ES, Lutgendorf SK, Sood AK, Anderson B, Sorosky J, Lubaroff DM: Psychosocial factors and interleukin-6 among women with advanced ovarian cancer. Cancer 104, 305-313 (2005).
111. Van Snick J: Interleukin-6: an overview. Annu. Rev. Immunol. 8, 253-278 (1990).
112. Obata NH, Tamakoshi K, Shibata K et al.: Effects of interleukin-6 on in vitro cell attachment, migration and invasion of human ovarian carcinoma. Anticancer Res. 17(1A), 337-342 (1997).
113. Wu S, Rodabaugh K, Martinez-Maza O et al.: Stimulation of ovarian tumor cell proliferation with monocyte products including interleukin-1, interleukin-6, and tumor necrosis factor-a. Am. J. Obstet. Gynecol. 166(3), 997-1007 (1992).
114. Nilsson MB, Langley RR, Fidler IJ: Interleukin-6, secreted by human ovarian carcinoma cells, is a potent proangiogenic cytokine. Cancer Res. 65(23), 10794-10800 (2005).
115. Nilsson MB, Armaiz-Pena G, Takahashi R et al.: Stress hormones regulate interleukin-6 expression by human ovarian carcinoma cells through a Src-dependent mechanism. J. Biol. Chem. 282(41), 29919-29926 (2007).
116. Yang EV, Sood AK, Chen M et al.: Norepinephrine up-regulates the expression of vascular endothelial growth factor, matrix metalloproteinase (MMP)-2, and MMP-9 in nasopharyngeal carcinoma tumor cells. Cancer Res. 66(21), 10357-10364 (2006).
117. Landen CN, Lin YG, Armaiz Pena GN et al.: Neuroendocrine modulation of signal transducer and activator of transcription-3 in ovarian cancer. Cancer Res. 67(21), 10389-10396 (2007).
118. Machein MR, Kullmer J, Ronicke V et al.: Differential downregulation of vascular endothelial growth factor by dexamethasone in normoxic and hypoxic rat glioma cells. Neuropathol. Appl. Neurobiol. 25(2), 104-112 (1999).
119. Fidler IJ: Critical factors in the biology of human cancer metastasis: twenty-eighth GHA Clowes Memorial Award Lecture. Cancer Res. 50(19), 6130-6138 (1990).
120. Flaxman BA, Harper RA: In vitro analysis of the control of keratinocyte proliferation in human epidermis by physiologic and pharmacologic agents. J. Invest. Dermatol. 65(1), 52-59 (1975).
121. Vandewalle B, Revillion F, Lefebvre J: Functional b-adrenergic receptors in breast cancer cells. J. Cancer Res. Clin. Oncol. 116(3), 303-306 (1990).
122. Marchetti B, Spinola PG, Pelletier G et al.: A potential role for catecholamines in the development and progression of carcinogen-induced mammary tumors: hormonal control of b-adrenergic receptors and correlation with tumor growth. J. Steroid Biochem. Mol. Biol. 38(3), 307-320 (1991).
123. Abramovitch R, Tavor E, Jacob-Hirsch J et al.: A pivotal role of cyclic AMP-responsive element binding protein in tumor progression. Cancer Res. 64(4), 1338-1346 (2004).
124. Lang K, Drell TL 4th, Lindecke A et al.: Induction of a metastatogenic tumor cell type by neurotransmitters and its pharmacological inhibition by established drugs. Int. J. Cancer 112(2), 231-238 (2004).
125. Jean D, Bar-Eli M: Regulation of tumor growth and metastasis of human melanoma by the CREB transcription factor family. Mol. Cell. Biochem. 212(1-2), 19-28 (2000).
126. Scarparo AC, Sumida D, Patrao MT et al.: Catecholamine effects on human melanoma cells evoked by a1-adrenoceptors. Arch. Dermatol. Res. 296(3), 112-119 (2004).
127. Pifl C, Zezula J, Spittler A et al.: Antiproliferative action of dopamine and norepinephrine in neuroblastoma cells expressing the human dopamine transporter. FASEB J. 15(9), 1607-1609 (2001).
128. Cox ME, Deeble PD, Lakhani S et al.: Acquisition of neuroendocrine characteristics by prostate tumor cells is reversible: implications for prostate cancer progression. Cancer Res. 59(15), 3821-3830 (1999).
129. Cohen RJ, Glezerson G, Haffejee Z: Neuroendocrine cells - a new prognostic parameter in prostate cancer. Br. J. Urol. 68(3), 258-262 (1991).
130. Theodorescu D, Broder SR, Boyd JC et al.: Cathepsin D and chromogranin A as predictors of long term disease specific survival after radical prostatectomy for localized carcinoma of the prostate. Cancer 80(11), 2109-2119 (1997).
131. di SantAgnese PA: Neuroendocrine differentiation in human prostatic carcinoma. Hum. Pathol. 23(3), 287-296 (1992).
132. Zhao XY, Malloy PJ, Krishnan AV et al.: Glucocorticoids can promote androgen-independent growth of prostate cancer cells through a mutated androgen receptor. Nat. Med. 6(6), 703-706 (2000).
133. Simon WE, Albrecht M, Trams G et al.: In vitro growth promotion of human mammary carcinoma cells by steroid hormones, tamoxifen, and prolactin. J. Natl Cancer Inst. 73(2), 313-321 (1984).
134. Boudreau N, Bissell MJ: Extracellular matrix signaling: integration of form and function in normal and malignant cells. Curr. Opin. Cell. Biol. 10(5), 640-646 (1998).
135. Biology of the Extracellular Matrix (2nd edition). Hay ED (Ed.). Plenum Press, NY, USA (1991).
136. Hynes RO: Integrins: versatility, modulation, and signaling in cell adhesion. Cell 69(1), 11-25 (1992).
137. Mercurio AM, Rabinovitz I: Towards a mechanistic understanding of tumor invasion - lessons from the a6b-4 integrin. Semin. Cancer Biol. 11(2), 129-141 (2001).
138. Kawasaki H, Springett GM, Mochizuki N et al.: A family of cAMP-binding proteins that directly activate Rap1. Science 282(5397), 2275-2279 (1998).
139. de Rooij J, Zwartkruis FJ, Verheijen MH et al.: Epac is a Rap1 guanine-nucleotide-exchange factor directly activated by cyclic AMP. Nature 396(6710), 474-477 (1998).
140. Rangarajan S, Enserink JM, Kuiperij HB et al.: Cyclic AMP induces integrin-mediated cell adhesion through Epac and Rap1 upon stimulation of the b2-adrenergic receptor. J. Cell Biol. 160(4), 487-493 (2003).
141. Enserink JM, Price LS, Methi T et al.: The cAMP-Epac-Rap1 pathway regulates cell spreading and cell adhesion to laminin-5 through the a3b1 integrin but not the a6b4 integrin. J. Biol. Chem. 279(43), 44889-44896 (2004).
142. Yang EV, Bane CM, MacCallum RC et al.: Stress-related modulation of matrix metalloproteinase expression. J. Neuroimmunol. 133(1-2), 144-150 (2002).
143. Wu W, Yamaura T, Murakami K et al.: Involvement of TNF-a in enhancement of invasion and metastasis of colon 26-L5 carcinoma cells in mice by social isolation stress. Oncol. Res. 11(10), 461-469 (1999).
144. Entschladen F, Lang K, Drell TL et al.: Neurotransmitters are regulators for the migration of tumor cells and leukocytes. Cancer Immunol. Immunother. 51(9), 467-482 (2002).
145. Masur K, Niggemann B, Zanker KS et al.: Norepinephrine-induced migration of SW 480 colon carcinoma cells is inhibited by b-blockers. Cancer Res. 61(7), 2866-2869 (2001).
146. Joseph J, Niggemann B, Zaenker KS et al.: The neurotransmitter g-aminobutyric acid is an inhibitory regulator for the migration of SW 480 colon carcinoma cells. Cancer Res. 62(22), 6467-6469 (2002).
147. Sood AK, Bhatty R, Kamat AA et al.: Stress hormone-mediated invasion of ovarian cancer cells. Clin. Cancer Res. 12(2), 369-375 (2006).
148. Drell T, Joseph J, Lang K et al.: Effects of neurotransmitters on the chemokinesis and chemotaxis of MDA-MB-468 human breast carcinoma cells. Breast Cancer Res. Treat. 80(1), 63-70 (2003).
149. Pollard J: Tumour-educated macrophages promote tumour progression and metastasis. Nat. Rev. Cancer 4, 71-78 (2004).
150. Coussens LM Werb Z: Inflammation and cancer. Nat. Rev. Cancer 420, 860-867 (2002).
151. Chan AS, Ng LW, Poon LS, Chan WW, Wong YH: Dopaminergic and adrenergic toxicities on SK-N-MC human neuroblastoma cells are mediated through G protein signaling and oxidative stress. Apoptosis 12, 167-179 (2007).
152. Sastry K: Epinephrine protects cancer cells from apoptosis via activation of cAMP-dependent protein kinase and BAD phosphorylation. J. Biol. Chem. 282, 14094-14100 (2007).
153. Distelhorst CW: Recent insights into the mechanism of glucocorticosteroid-induced apoptosis. Cell Death Differ. 9(1), 6-19 (2002).
154. Herr I, Ucur E, Herzer K et al.: Glucocorticoid cotreatment induces apoptosis resistance toward cancer therapy in carcinomas. Cancer Res. 63(12), 3112-3120 (2003).
155. Wu W, Chaudhuri S, Brickley DR et al.: Microarray analysis reveals glucocorticoid-regulated survival genes that are associated with inhibition of apoptosis in breast epithelial cells. Cancer Res. 64(5), 1757-1764 (2004).
156. Zhang C, Kolb A, Buchler P et al.: Corticosteroid co-treatment induces resistance to chemotherapy in surgical resections, xenografts and established cell lines of pancreatic cancer. BMC Cancer 6, 61 (2006).
157. Bekasi S, Zalatnai A: Overexpression of glucocorticoid receptor in human pancreatic cancer and in xenografts. An immunohistochemical study. Pathol. Oncol. Res. 15(4), 561-566 (2009).
158. Zhang C, Kolb A, Mattern J et al.: Dexamethasone desensitizes hepatocellular and colorectal tumours toward cytotoxic therapy. Cancer Lett. 242(1), 104-111 (2006).
159. Zhang C, Beckermann B, Kallifatidis G et al.: Corticosteroids induce chemotherapy resistance in the majority of tumour cells from bone, brain, breast, cervix, melanoma and neuroblastoma. Int. J. Oncol. 29(5), 1295-1301 (2006).
160. Zhang C, Marme A, Wenger T et al.: Glucocorticoid-mediated inhibition of chemotherapy in ovarian carcinomas. Int. J. Oncol. 28(2), 551-558 (2006).
161. Zhang C, Wenger T, Mattern J et al.: Clinical and mechanistic aspects of glucocorticoid-induced chemotherapy resistance in the majority of solid tumors. Cancer Biol. Ther. 6(2), 278-287 (2007).
162. Sood AK, Armaiz-Pena GN, Halder J et al.: Adrenergic modulation of focal adhesion kinase protects human ovarian cancer cells from anoikis. J. Clin. Invest. 120(5), 1515-1523 (2010).
163. Dave JR, Anderson SM, Saviolakis GA et al.: Chronic sustained stress increases levels of anterior pituitary prolactin mRNA. Pharmacol. Biochem. Behav. 67(3), 423-431 (2000).
164. Almeida SA, Petenusci SO, Franci JA et al.: Chronic immobilization- induced stress increases plasma testosterone and delays testicular maturation in pubertal rats. Andrologia 32(1), 7-11 (2000).
165. Young WS 3rd, Lightman SL: Chronic stress elevates enkephalin expression in the rat paraventricular and supraoptic nuclei. Brain Res. Mol. Brain Res. 13(1-2), 111-117 (1992).
166. Glavin GB, Szabo S: Dopamine in gastrointestinal disease. Dig. Dis. Sci. 35(9), 1153-1161 (1990).
167. Mezey E, Eisenhofer G, Hansson S et al.: Dopamine produced by the stomach may act as a paracrine/autocrine hormone in the rat. Neuroendocrinology 67(5), 336-348 (1998).
168. Thaker PH, Sood AK: Neuroendocrine influences on cancer biology. Semin. Cancer Biol. 18, 164-170 (2007).
169. Basu S, Nagy JA, Pal S et al.: The neurotransmitter dopamine inhibits angiogenesis induced by vascular permeability factor/vascular endothelial growth factor. Nat. Med. 7(5), 569-574 (2001). (Pubitemid 32448324)
170. Teunis MA, Kavelaars A, Voest E et al.: Reduced tumor growth, experimental metastasis formation, and angiogenesis in rats with a hyperreactive dopaminergic system. FASEB J. 16(11), 1465-1467 (2002).
171. Chakroborty D, Sarkar C, Basu B et al.: Catecholamines regulate tumor angiogenesis. Cancer Res. 69(9), 3727-3730 (2009).
172. Basu S, Sarkar C, Chakroborty D et al.: Ablation of peripheral dopaminergic nerves stimulates malignant tumor growth by inducing vascular permeability factor/ vascular endothelial growth factor-mediated angiogenesis. Cancer Res. 64, 5551-5555 (2004).
173. Chakroborty D, Sarkar C, Mitra RB et al.: Depleted dopamine in gastric cancer tissues: dopamine treatment retards growth of gastric cancer by inhibiting angiogenesis. Clin. Cancer Res. 10(13), 4349-4356 (2004).
174. Sarkar C, Chakroborty D, Chowdhury UR et al.: Dopamine increases the efficacy of anticancer drugs in breast and colon cancer preclinical models. Clin. Cancer Res. 14(8), 2502-2510 (2008).
175. Chakroborty D, Chowdhury UR, Sarkar C et al.: Dopamine regulates endothelial progenitor cell mobilization from mouse bone marrow in tumor vascularization. J. Clin. Invest. 118(4), 1380-1389 (2008).
176. Moreno-Smith M, Armaiz-Pena GN, Allen JK et al.: Dopamine blocks stress-mediated tumor growth in ovarian carcinoma. Presented at: 100th Annual Meeting of American Association for Cancer Resesarch. Denver, CL, USA, 18-22 April 2009.
177. Clevenger CV, Furth PA, Hankinson SE et al.: The role of prolactin in mammary carcinoma. Endocr. Rev. 24(1), 1-27 (2003).
178. Ben-Jonathan N, Liby K, McFarland M et al.: Prolactin as an autocrine/paracrine growth factor in human cancer. Trends Endocrinol. Metab. 13(6), 245-250 (2002).
179. Vonderhaar BK: Prolactin in human breast cancer development. In: Endocrine Oncology. Stephen PE (Ed.). Humana Press, NJ, USA, 101-120 (2000)
180. Chen WY, Ramamoorthy P, Chen N et al.: A human prolactin antagonist, HPRL-G129R, inhibits breast cancer cell proliferation through induction of apoptosis. Clin. Cancer Res. 5(11), 3583-3593 (1999).
181. Richert MM, Decker K, Anderson SM: Mechanisms underlying consitutive activation of Akt in breast cancer cell lines. Presented at: 83rd Annual Meeting of the Endocrine Society. Denver, CO, USA, 20-23 June 2001.
182. Maus MV, Reilly SC, Clevenger CV: Prolactin as a chemoattractant for human breast carcinoma. Endocrinology 140(11), 5447-5450 (1999).
183. Ben-Jonathan N, Hnasko R: Dopamine as a prolactin inhibitor. Endocr. Rev. 22(6), 724-763 (2001).
184. Grewen KM, Girdler SS, Amico J, Light KC: Effects of partner support on resting oxytocin, cortisol, norepinephrine, and blood pressure before and after warm partner contact. Psychosom. Med. 67(4), 531-538 (2005).
185. McCarthy MM, McDonald CH, Brooks PJ, Goldman D: An anxiolytic action of oxytocin is enhanced by estrogen in the mouse. Physiol. Behav. 60(5), 1209-1215 (1996).
186. Jezova D, Skultetyova I, Vedhara K et al.: Vasopressin and oxytocin in stress. Ann. NY Acad. Sci. 771, 192-203 (1995).
187. Pequeux C, Keegan BP, Hagelstein MT et al.: Oxytocin-and vasopressin-induced growth of human small-cell lung cancer is mediated by the mitogen-activated protein kinase pathway. Endocr. Relat. Cancer 11(4), 871-885 (2004).
188. Cassoni P, Marrocco T, Deaglio S et al.: Biological relevance of oxytocin
189. Taylor AH, Ang VT, Jenkins JS et al.: Interaction of vasopressin and oxytocin with human breast carcinoma cells. Cancer Res. 50(24), 7882-7886 (1990).
190. Bussolati GC: The oxytocin/oxytocin receptor system - expect the unexpected. Endocrinology 142(4), 1377-1379 (2001).
191. Reversi A, Cassoni P, Chini B: Oxytocin receptor signaling in myoepithelial and cancer cells. J. Mammary Gland Biol. Neoplasia 10(3), 221-229 (2006).
192. Péqueux C, Breton C, Hendrick JC et al.: Oxytocin synthesis and oxytocin receptor expression by cell lines of human small cell carcinoma of the lung stimulate tumor growth through autocrine/paracrine signaling. Cancer Res. 4623-4629 (2002).
193. Mantyh P: Neurobiology of substance P and the NK1 receptor. J. Clin. Psychiatry 63, 6-10 (2002).
194. Kramer MS, Cutler N, Feighner J et al.: Distinct mechanism for antidepressant activity by blockade of central substance P receptors. Science 281, 1640-1645 (1998).
195. Ruff M, Schiffmann E, Terranova V et al.: Neuropeptides are chemoattractants for human tumor cells and monocytes: a possible mechanism for metastasis. Clin. Immunol. Immunopathol. 37(3), 387-396 (1985).
196. Dragos D, Tanasescu MD: The effect of stress on the defense systems. J. Med. Life 3(1), 10-18 (2010).
197. Dhabhar FS, Saul AN, Daugherty C et al.: Short-term stress enhances cellular immunity and increases early resistance to squamous cell carcinoma. Brain Behav. Immun. 24(1), 127-137 (2010).
198. Knutson KL Disis ML: Tumor antigen-specific T helper cells in cancer immunity and immunotherapy. Cancer Immunol. Immunother. 54, 721-728 (2005).
199. Webster JI, Tonelli L, Sternberg EM: Neuroendocrine regulation of immunity. Annu. Rev. Immunol. 20, 125-163 (2002).
200. Calcagni E, Elenkov I: Stress system activity, innate and T helper cytokines, and susceptibility to immune-related diseases. Ann. NY Acad. Sci. 1069, 62-76 (2006).
201. Kryczek I, Wei S, Zou L et al.: Cutting edge: Th17 and regulatory T cell dynamics and the regulation by IL-2 in the tumor microenvironment. J. Immunol. 178(11), 6730-6733 (2007).
202. Zhang B, Rong R, Wei H et al.: The prevalence of Th17 cells in patients with gastric cancer. Biochem. Biophys. Res. Commun. 374(3), 533-537 (2008).
203. Curiel TJ: Regulatory T cells and treatment of cancer. Curr. Opin. Immunol. 20(2), 241-246 (2008).
204. Vedhara K, Cox NK, Wilcock GK et al.: Chronic stress in elderly carers of dementia patients and antibody response to influenza vaccination. Lancet 353(9153), 627-631 (1999). (Pubitemid 29087983)
205. Kiecolt-Glaser JK, Ricker D, George J et al.: Urinary cortisol levels, cellular immunocompetency, and loneliness in psychiatric inpatients. Psychosom. Med. 46(1), 15-23 (1984).
206. Aloyz RS, Bamji SX, Pozniak CD et al.: p53 is essential for developmental neuron death as regulated by the TRKA and p75 neurotrophin receptors. J. Cell Biol. 143(6), 1691-1703 (1998).
207. Elenkov I: Systemic stress-induced Th2 shift and its clinical implications. J. Int. Rev. Neurobiol. 52, 163-186 (2002).
208. Almog B, Fainaru O, Gamzu R et al.: Placental apoptosis in discordant twins. Placenta 23(4), 331-336 (2002).
209. Madden KS, Sanders VM, Felten DL: Catecholamine influences and sympathetic neural modulation of immune responsiveness. Annu. Rev. Pharmacol. Toxicol. 35, 417-448 (1995).
210. Brodde OE, Engel G, Hoyer D et al.: The b-adrenergic receptor in human lymphocytes: subclassification by the use of a new radio-ligand ± 125 iodocyanopindolol. Life Sci. 29(21), 2189-2198 (1981).
211. Fuchs BA, Campbell KS, Munson AE: Norepinephrine and serotonin content of the murine spleen: its relationship to lymphocyte b-adrenergic receptor density and the humoral immune response in vivo and in vitro. Cell Immunol. 117(2), 339-351 (1988).
212. Landmann R, Bittiger H, Buhler FR: High affinity b-2-adrenergic receptors in mononuclear leucocytes: similar density in young and old normal subjects. Life Sci. 29(17), 1761-1771 (1981). (Pubitemid 12215088)
213. Loveland BE, Jarrott B, McKenzie IF: The detection of b-adrenoceptors on murine lymphocytes. Int. J. Immunopharmacol. 3(1), 45-55 (1981).
214. Titinchi S, Clark B: a2-adrenoceptors in human lymphocytes: direct characterisation by [3H]yohimbine binding. Biochem. Biophys. Res. Commun. 121(1), 1-7 (1984).
215. McPherson GA, Summers RJ: Characterization and localization of 3H-clonidine binding in membranes prepared from guinea-pig spleen. Clin. Exp. Pharmacol. Physiol. 9(1), 77-87 (1982).
216. Goin JC, Sterin-Borda L, Borda ES et al.: Active a-2 and b-adrenoceptors in lymphocytes from patients with chronic lymphocytic leukemia. Int. J. Cancer 49(2), 178-181 (1991).
217. Abrass CK, OConnor SW, Scarpace PJ et al.: Characterization of the b-adrenergic receptor of the rat peritoneal macrophage. J. Immunol. 135(2), 1338-1341 (1985).
218. Spengler RN, Allen RM, Remick DG et al.: Stimulation of a-adrenergic receptor augments the production of macrophage-derived tumor necrosis factor. J. Immunol. 145(5), 1430-1434 (1990).
219. Plaut M: Lymphocyte hormone receptors. Annu. Rev. Immunol. 5, 621-669 (1987).
220. Yukawa T, Ukena D, Kroegel C et al.: b-2-adrenergic receptors on eosinophils. Binding and functional studies. Am. Rev. Respir. Dis. 141(6), 1446-1452 (1990).
221. Hadden JW, Hadden EM, Middleton E: Lymphocyte blast transformation. I. Demonstration of adrenergic receptors in human peripheral lymphocytes. Cell Immunol. 1(6), 583-595 (1970).
222. Melmon KL, Bourne HR, Weinstein Y et al.: Hemolytic plaque formation by leukocytes in vitro. Control by vasoactive hormones. J. Clin. Invest. 53(1), 13-21 (1974).
223. Bourne HR, Lichtenstein LM, Melmon KL et al.: Modulation of inflammation and immunity by cyclic AMP. Science 184(132), 19-28 (1974).
224. Depelchin A, Letesson JJ: Adrenaline influence on the immune response. I. Accelerating or suppressor effects according to the time of application. Immunol. Lett. 3(4), 199-205 (1981). (Pubitemid 12252944)
225. Gader AM: The effects of b-adrenergic blockade on the responses of leucocyte counts to intravenous epinephrine in man. Scand. J. Haematol. 13(1), 11-16 (1974).
226. Crary B, Borysenko M, Sutherland DC et al.: Decrease in mitogen responsiveness of mononuclear cells from peripheral blood after epinephrine administration in humans. J. Immunol. 130(2), 694-697 (1983).
227. Dunn GP, Bruce AT, Ikeda H et al.: Cancer immunoediting: from immunosurveillance to tumor escape. Immunol. Nat. 3, 991-998 (2002).
228. Saul AN, Oberyszyn TM, Daugherty C et al.: Chronic stress and susceptibility to skin cancer. J. Natl Cancer Inst. 97(23), 1760-1767 (2005).
229. Greenfeld K, Avraham R, Benish M et al.: Immune suppression while awaiting surgery and following dissociations between plasma cytokine levels, their induced production, and NK cell cytotoxicity. Brain Behav. Immun. 21, 503-513 (2007).
230. Kiecolt-Glaser JK, Fisher LD, Ogrocki P, Stout JC, Speicher CE, Glaser R: Marital quality, marital disruption, and immune function. Psychosom. Med. 49, 13-34 (1987).
231. Zorilla EP, Luborsky L, McKay JR et al.: The relationship of depression and stressors to immunological assays: a meta-analytic review. Brain Behav. Immun. 15, 199-226 (2001).
232. Irwin M: Psychoneuroimmunology of depression: clinical implications. Brain Behav. Immun. 16(1), 1-16 (2002).
233. Blomberg BB, Alvarez JP, Diaz A et al.: Psychosocial adaptation and cellular immunity in breast cancer patients in the weeks after surgery: an exploratory study. J. Psychosom. Res. 67, 369-376 (2009).
234. Andersen BL, Farrar WB, Golden-Kreutz D et al.: Stress and immune responses after surgical treatment for regional breast cancer. J. Natl Cancer Inst. 90(1), 30-36 (1998).
235. Thornton LM, Andersen BL, Crespin TR, Carson WE: Individual trajectories in stress covary with immunity during recovery from cancer diagnosis and treatments. Brain Behav. Immun. 21, 185-194 (2007).
236. Thornton LM, Andersen BL, Carson WE 3rd: Immune, endocrine, and behavioral precursors to breast cancer recurrence: a case-control analysis. Cancer Immunol. Immunother. 57(10), 1471-1481 (2008).
237. Sephton SE, Dhabhar FS, Keuroghlian AS et al.: Depression, cortisol, and suppressed cell-mediated immunity in metastatic breast cancer. Brain Behav. Immun. 23(8), 1148-1155 (2009).
238. Lutgendorf SK, Sood AK, Anderson B et al.: Social support, psychological distress, and natural killer cell activity in ovarian cancer. J. Clin. Oncol. 23(28), 7105-7113 (2005).
239. Lutgendorf SK, Lamkin DM, DeGeest K et al.: Depressed and anxious mood and T-cell cytokine producing populations in ovarian cancer patients. Brain Behav. Immun. 22, 890-900 (2008).
240. Glasner A, Avraham R, Rosenne E et al.: Improving survival rates in two models of spontaneous postoperative metastasis in mice by combined administration of a b-adrenergic antagonist and a cyclooxygenase-2 inhibitor. J. Immunol. 184(5), 2449-2457 (2010).
241. Basu S, Dasgupta PS, Lahiri T et al.: Uptake and biodistribution of dopamine in bone marrow, spleen and lymph nodes of normal and tumor bearing mice. Life Sci. 53(5), 415-424 (1993).
242. Basu S, Dasgupta PS, Chowdhury JR: Enhanced tumor growth in brain dopamine-depleted mice following 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) treatment. J. Neuroimmunol. 60(1-2), 1-8 (1995).
243. Marttila RJ, Eskola J, Päivärinta M, Rinne UK: Immune functions in Parkinsons disease. Adv. Neurol. 40, 315-323 (1984).
244. Marttila RJ, Eskola J, Soppi E, Rinne UK: Immune functions in Parkinsons disease lymphocyte subsets, concanavalin A-induced suppressor cell activity and in vitro immunoglobulin production. J. Neurol. Sci. 69(3), 121-131 (1985).
245. Fiszer U, Piotrowska K, Korlak J et al.: The immunological status in Parkinsons disease. Med. Lab. Sci. 48(3), 196-200 (1991).
246. Villemain F, Chatenoud L, Galinowski A et al.: Aberrant T cell-mediated immunity in untreated schizophrenic patients: deficient interleukin-2 production. Am. J. Psychiatry 146(5), 609-616 (1989).
247. Ganguli R, Brar JS, Chengappa KR et al.: Mitogen-stimulated interleukin-2 production in never-medicated, first-episode schizophrenic patients. The influence of age at onset and negative symptoms. Arch. Gen. Psychiatry 52(8), 668-672 (1995).
248. Maes M, Bosmans E, Calabrese J et al.: Interleukin-2 and interleukin-6 in schizophrenia and mania: effects of neuroleptics and mood stabilizers. J. Psychiatr. Res. 29(2), 141-152 (1995).
249. Mortensen PB: The incidence of cancer in schizophrenic patients. J. Epidemiol. Commun. Health 43(1), 43-47 (1989).
250. Goldacre M, Kurina L, Wotton C et al.: Schizophrenia and cancer: an epidemiological study. Br. J. Psychiatry 187, 334-338 (2005).
251. Asada M, Ebihara S, Numachi Y et al.: Reduced tumor growth in a mouse model of schizophrenia lacking the dopamine transporter. Int. J. Cancer 123, 511-518 (2008).
252. Barak Y, Achiron A, Mandel M et al.: Reduced cancer incidence among patients with schizophrenia. Cancer 104(12), 2817-2821 (2005).
253. Antoni MH, Lutgendorf SK, Cole SW et al.: The influence of bio-behavioural factors on tumour biology: pathways and mechanisms. Nat. Rev. Cancer 6(3), 240-248 (2006).
254. Perron L, Bairati I, Harel F et al.: Antihypertensive drug use and the risk of prostate cancer (Canada). Cancer Causes Control 15(6), 535-541 (2004).
255. Algazi M, Plu-Bureau G, Flahault A et al.: Could treatments with b-blockers be associated with a reduction in cancer risk? Rev. Epidemiol. Sante Publique 52(1), 53-65 (2004).
256. Li CI, Malone KE, Weiss N et al.: Relation between use of antihypertensive medications and risk of breast carcinoma among women ages 65-79 years. Cancer 98(7), 1504-1513 (2003). (Pubitemid 37151507)
257. Meier CR, Derby LE, Jick SS et al.: Angiotensin-converting enzyme inhibitors, calcium channel blockers, and breast cancer. Arch. Intern. Med. 160(3), 349-353 (2000).
258. Rosenberg L, Rao RS, Palmer JR et al.: Calcium channel blockers and the risk of cancer. JAMA 279(13), 1000-1004 (1998).
259. Cao L, Liu X, Lin EJ et al.: Environmental and genetic activation of a brain-adipocyte BDNF/leptin axis causes cancer remission and inhibition. Cell 142(1), 52-64 (2010).
260. Khong HT, Restifo NP: Natural selection of tumor variants in the generation of tumor escape phenotypes. Nat. Immunol. 3, 999-1005 (2002).
261. Benish M, Bartal I, Goldfarb Y et al.: Perioperative use of b-blockers and COX-2 inhibitors may improve immune competence and reduce the risk of tumor metastasis. Ann. Surg. Oncol. 15, 2042-2052 (2008).